Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H9N2O3S.Na |
| Molecular Weight | 236.223 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1
InChI
InChIKey=PQMSFAORUFMASU-UHFFFAOYSA-M
InChI=1S/C8H10N2O3S.Na/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8;/h2-5H,9H2,1H3,(H,10,11);/q;+1/p-1
| Molecular Formula | C8H10N2O3S |
| Molecular Weight | 214.242 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2364668 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | BLEPHAMIDE Approved UseBlephamide ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. Launch Date1961 |
|||
| Curative | KLARON Approved UseKlaron Lotion is indicated in the topical treatment of acne vulgaris. Launch Date1996 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. | 1990 Feb |
|
| [The effective antibacterial spectrum of sulfacetamide]. | 1992 Mar |
|
| Spectrophotometric determination of sulphacetamide. | 2002 Jul-Aug |
|
| Iminodibenzyl as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives. | 2002 Mar |
|
| A status report on the medical management of rosacea: focus on topical therapies. | 2002 Nov |
|
| Route of antibiotic administration for conjunctivitis. | 2002 Oct |
|
| Determination of prednisolone and the most important associated compounds in ocular and cutaneous pharmaceutical preparations by micellar electrokinetic capillary chromatography. | 2003 Jan 25 |
|
| New drugs and dosage forms. | 2003 Mar 1 |
|
| Actinomyces canaliculitis: diagnosis of a masquerading disease. | 2004 Aug |
|
| Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection. | 2004 Aug 20 |
|
| Rosacea. An overview of diagnosis and management. | 2004 Dec |
|
| Medical treatment of rosacea with emphasis on topical therapies. | 2004 Jan |
|
| Facial hygiene and comprehensive management of rosacea. | 2004 Mar |
|
| Sulfur/sodium sulfacetamide preparations. | 2004 Mar-Apr |
|
| Diagnosis and treatment of acne. | 2004 May 1 |
|
| Rosacea: where are we now? | 2004 May-Jun |
|
| Laboratory exposures to staphylococcal enterotoxin B. | 2004 Sep |
|
| Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum. | 2004 Sep |
|
| Diagnosing and managing the patient with rosacea. | 2005 Apr |
|
| Topical metronidazole combination therapy in the clinical management of rosacea. | 2005 Jul-Aug |
|
| Adjunctive skin care in the management of rosacea: cleansers, moisturizers, and photoprotectants. | 2005 Mar |
|
| Simultaneous determination of 16 sulfonamides in honey by liquid chromatography/tandem mass spectrometry. | 2005 Sep-Oct |
|
| Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. | 2006 Apr |
|
| Researches concerning the synthesis and antituberculosis action of some new sulphacetamide derivatives. | 2006 Apr-Jun |
|
| Combination topical therapy in the treatment of acne. | 2006 Aug |
|
| Toxicity and biodegradability of sulfonamides and products of their photocatalytic degradation in aqueous solutions. | 2006 Nov |
|
| Determination of sulfonamide antibiotics in wastewater: a comparison of solid phase microextraction and solid phase extraction methods. | 2006 Oct 27 |
|
| Pilot investigation of the hydrating effects of topical acne medications. | 2007 Aug |
|
| Simultaneous determination of 17 sulfonamides and the potentiators ormetoprim and trimethoprim in salmon muscle by liquid chromatography with tandem mass spectrometry detection. | 2007 Jan-Feb |
|
| [Determination of 12 sulfonamides in cosmetics by ultra performance liquid chromatography]. | 2007 Mar |
|
| A sensitive spectrophotometric method for the determination of sulfonamides in pharmaceutical preparations. | 2007 Sep |
|
| N-(2,6-Dimethyl-phen-yl)-2-methyl-acetamide. | 2008 Jan 9 |
|
| Comparative study of robustness between micellar electrokinetic capillary chromatography and high-performance liquid chromatography using one-variable-at-a-time and a new multi-variable-at-a-time approach. | 2008 Jul 14 |
|
| Bioadhesive sulfacetamide sodium microspheres: evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model. | 2009 Aug |
|
| Rosacea and its topical management. | 2009 Feb |
|
| Analytical method for simultaneous determination of pesticide and veterinary drug residues in milk by CE-MS. | 2009 May |
|
| A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. | 2009 Oct 23 |
|
| Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery. | 2010 |
|
| An alternative purification method for human serum paraoxonase 1 and its interactions with sulfonamides. | 2010 Dec |
|
| [Rosacea: pathogenesis, clinical forms and therapy]. | 2010 Jul 25 |
|
| Pharmacokinetic study on the mechanism of interaction of sulfacetamide sodium with bovine serum albumin: a spectroscopic method. | 2010 Mar |
|
| Synthesis of novel selenium-containing sulfa drugs and their antibacterial activities. | 2010 May-Jun |
|
| Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. | 2010 Nov |
|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Patents
Sample Use Guides
Topical: apply a thin film to affected areas twice daily. Ophtalmic suspension/ointment: two drops of suspension should be instilled into the conjunctival sac every four hours during the day and at bedtime. A small amount, approximately 1/2 inch ribbon of ointment, should be applied in the conjunctival sac three or four times daily and once or twice at night.
Route of Administration:
Other
P. aeruginosa, S. marcescens, St. epidermidis, C.
albicans, and A. fumigatus (spores) were exposed to two ophthalmic solutions each formulated with 10% sodium sulfacetamide and a preservative. Sulfacetamide solutions preserved with thimerosal have MIC values ranging from 0.2 to 2.8 for the five test microorganisms. The solutions preserved with parabens exhibit slightly higher MIC values for Pseudomonas, Serratia, and spores of Aspergillus (1.5-6.5) and significantly higher MIC values for Staphylococcus and Candida (19.6 and 5.0, respectively).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 03:58:55 GMT 2023
by
admin
on
Sat Dec 16 03:58:55 GMT 2023
|
| Record UNII |
30760ZE777
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB20814
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
9327
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
4022878
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
204-848-4
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
127-56-0
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
63858
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
DTXSID40889336
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
m10301
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
30760ZE777
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |